Ignite Creation Date:
2024-05-06 @ 1:23 AM
Last Modification Date:
2024-10-26 @ 11:03 AM
Study NCT ID:
NCT01799473
Status:
COMPLETED
Last Update Posted:
2015-03-24
First Post:
2013-02-12
Brief Title:
Tyvaso Dosing and Titration Evaluation TyTRATE Registry
Sponsor:
United Therapeutics
Organization:
United Therapeutics
Study Overview
Official Title:
A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective observational multi-center patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension PAH Once enrolled the patients dose and titration will be followed for the first 6 months of treatment with Tyvaso
A call-center will contact the patients directly at weeks 1 2 3 4 8 12 16 20 and 24 to review their dose and titration schedule In addition to patient-reported dosing data some patient demographic information will be collected by the investigative site at Baseline
A call-center will contact the patients directly at weeks 1 2 3 4 8 12 16 20 and 24 to review their dose and titration schedule In addition to patient-reported dosing data some patient demographic information will be collected by the investigative site at Baseline
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None